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Abstract
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Approximately 30,000 cases of non-Hodgkin lymphoma (NHL) occur in the equatorial belt of
Africa each year. Apart from the fact that Burkitt lymphoma (BL) is very common among children
and adolescents in Africa and that an epidemic of human immunodeficiency virus (HIV) infection
is currently ongoing in this part of the world, very little is known about lymphomas in Africa. This
review provides information regarding the current infrastructure for diagnostics in sub-Saharan
Africa. The results on the diagnostic accuracy and on the distribution of different lymphoma
subsets in sub-Saharan Africa were based on a review undertaken by a team of lymphoma experts
on159 fine needle aspirationsamples and 467 histological samples during their visit to the African
centres is presented. Among children (<18 years of age), BL accounted for 82% of all NHL, and
among adults, diffuse large B-cell lymphoma accounted for 55% of all NHLs. Among adults,
various lymphomas other than BL, including T-cell lymphomas, were encountered. The review
also discusses the current strategies of the International Network of Cancer Treatment and
Research on improving the diagnostic standards and management of lymphoma patients and in
acquiring reliable clinical and pathology data in sub-Saharan Africa for fostering high-quality
translational research.
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Although accurate estimates are difficult, given the paucity of information, it is likely that
approximately 30,000 cases of non-Hodgkin lymphoma (NHL) occur in the equatorial belt
of Africa each year and these tumours are among the top ten causes of cancer in this
geographical region. The fraction associated with acquired immunodeficiency syndrome
(AIDS) is not available, but may be as high as 50%, although it appears to vary markedly
throughout the region and is different among children and adults. The incidence of NHL
since the AIDS epidemic has increased by 2- to 3-fold in some countries, and as much as 13fold in others (Kaaya et al, 2006; Otieno et al, 2001; Orem et al, 2004). A realistic estimate
of the incidence of Burkitt Lymphoma (BL) is 30-70 per million children in equatorial
African countries. Apart from BL, the incidence for other lymphoma subtypes in equatorial
Africa remains unknown.

NIH-PA Author Manuscript

Meaningful research on lymphomas in African cannot be conducted without accurate
diagnosis. Unfortunately, striking differences still exist with respect to the reliability of
lymphoma diagnosis between developed and developing countries, due partly to the limited
number of haematopathologists and partly to the lack of special reagents, such as
monoclonal antibodies and molecular probes that are indispensable to an accurate diagnosis
based on the World Health Organization (WHO) classification of haematopoietic and
lymphoid tissues (Swerdlow et al, 2008).
Unfortunately, the resource limitations (human and material) in Africa severely restrict the
ability to make an accurate diagnosis early in the disease course and provide adequate
treatment and follow-up for patients, thus fostering a belief that therapy is pointless.
However, with improved education and relatively simple augmentation of resources, quite
simple chemotherapy regimens that require less supportive care are, in fact, feasible in at
least major centres in Africa. Under the guidance of the International Network for Cancer
Treatment and Research (INCTR) (http://www.inctr.org/), many of the African centres are
currently treating lymphomas successfully with protocols specifically designed for the
prevailing infrastructure in these centres.
The INCTR team has been working in collaboration with many African partners to achieve:
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1.

Improvements in the speed and accuracy of diagnosis in Africa.

2.

Organization of advanced training of pathologists and technicians from the African
centres.

3.

Introduction of standard therapy, adapted to the African setting.

4.

Developing translational research studies partnering African and European
institutions.

To achieve these objectives, the authors, comprising a group of pathologists (along with
oncologists), have visited several African centres in teams to assess the infrastructure, audit
the diagnoses offered by the African investigators, introduce capacity building measures,
provide logistic support for telemedicine and assist with treatment protocols specifically
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designed for the African setting. As a follow up, the group has conducted annual educational
meetings in Europe attended by African investigators, European partners and other delegates
from across the world. Meetings have been held in Italy (Siena – May 2010) and France
(Paris – May 2011).
This review will focus on a) the current infrastructure for diagnostics in sub-Saharan Africa,
b) the current diagnostic accuracy in the African setting, c) the distribution of different
lymphoma subsets in institutions visited in sub-Saharan Africa, d) how diagnostic standards
can be improved, e) management strategies for lymphoma patients that are likely to yield the
best outcomes in sub-Saharan Africa, f) preliminary results of the INCTR-assisted treatment
protocols in sub-Saharan Africa, g) acquisition of reliable clinical and pathology data in subSaharan Africa, and h) strategies to foster high-quality translational research.

Infrastructure for diagnostics in sub-Saharan Africa

NIH-PA Author Manuscript
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During our visits, the infrastructure was found to be highly variable both in terms of
equipment and available personnel. The annual biopsy numbers varied between 1500 to
around 16000 among the cellular pathology departments visited. In addition, some of the
departments had a substantial cytology load, in one instance recording a volume of about
5000 cases annually. Fine needle aspiration cytology (FNAC) was widely utilized. The
availability of equipment was heterogeneous. Histokinettes for tissue/biopsy processing,
rotatory microtome for preparing histology slides, and autostainers were available in some
centres (especially those that had collaborations with institutions in developed countries).
Some of these also had facilities for cytospin preparations (especially for cerebrospinal
fluid) and for preparation of cell-blocks. In some centres, biopsies/tissue samples were
processed manually. Formalin was used as the tissue fixative in all the places visited.
Haematoxylin & Eosin (H&E) for histology preparation and H&E, Papanicolaou and May
Grünwald Giemsa stains for cytology samples were routinely used. In addition, some centres
were proficient in other histochemical stains that included Periodic acid Schiff, Grocott's
Gordon & Sweet (reticulin), Perl's Prussian blue (iron), Masson Trichrome, Ziehl Neelsen
(acid fast bacilli), Masson Fontana, Alcian blue, Mucicarmine, Congo red, Periodic acid
methenamine silver and Phosphotungstic acid haematoxylin. Turnaround time (TAT) for
histology depended on infrastructural capacity. Among centres with well-established
infrastructure, the TAT was less than a week, whereas it was substantially longer in centres
with suboptimal capacity.
The quality of histology and cytology preparations was variable. In most centres, the
standard was lower than what would be considered optimal in developed countries.
However, there were exceptions, where the quality of the H&E stained tissue sections were
comparable to the best centres in the world. The suboptimal quality of the material could be
attributed to poor fixation (over/under fixation or improperly prepared fixatives), suboptimal
tissue processing or suboptimal quality of tissue sectioning. Most of the centres had
adequate microscopes. The number of pathologists for the work-load was adequate, although
this should not be taken to apply at a national level - the number of available pathologists in
Tanzania was reported to be extremely low, and the country lacked pathology trainees.
Pathologists in training within the universities of Nairobi (Kenya) and Nigeria were highly
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motivated. Recent pathology textbooks and journals were not available in most centres.
Despite these drawbacks, pathologists were reasonably well informed.
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Although a proportion of the pathologists in sub-Saharan Africa had exposure to centres
abroad, the laboratory technical staff had not been trained at centres of excellence. Apart
from one privately-funded hospital, all other centres lacked facilities for
immunohistochemistry. All local pathologists acknowledged that the lack of
immunohistochemistry severely hampered their ability to diagnose and classify lymphoid
proliferations accurately.

Diagnostic accuracy in the African setting
A panel of lymphoma experts (varied between 3-5 among different centres) reviewed 159
FNA samples and 467 histological samples during the team's visit to the African centres.
The review process was as follows:
Independent review by the experts
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Each expert was provided with a microscope and writing material to record their diagnostic
impression in each case.
Consensus evaluation
Responses from each of the experts was analysed for consensus in each case. Consensus
among two of three, three of four or four of five experts was accepted and recorded as the
consensus diagnosis. Where a consensus diagnosis was achieved, cases were not further
discussed, unless there was educational value to the host pathologists and pathologists in
training. The Remainder of cases were considered discrepant.
Consensus discussion
All discrepant cases and those cases with consensus where the hosts wished to have further
discussion were examined during a “consensus discussion.” Cases in which there was
disagreement were re-evaluated by the experts. Following the discussion, consensus was
achieved by the experts in a proportion of the discrepant cases.
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Advice on follow-up investigations for histological samples
Cases with consensus required additional immunohistochemical investigations to conform to
the criteria essential for classification based on the current WHO recommendations.
Additional testing required was recorded in each case. In cases where a consensus diagnosis
was not reached despite discussion, a panel of tests and an algorithm for diagnosis was
documented on site.
Follow-up investigations for histological samples
Immunohistochemistry, in-situ hybridization (ISH) and fluorescent in-situ hybridization
(FISH) investigations were undertaken in European institutions under the guidance of
Professor L. Leoncini, and a final diagnosis was determined according to the decision-
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making algorithm prepared. A few cases required further discussion among the experts
during the meeting in Sienna (May 2010).
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Among the 159 FNA samples where a diagnosis of Burkitt lymphoma (BL) had been
suggested by the pathologists in sub-Saharan Africa, 76% were confirmed to be BL and in
an additional 12%, a diagnosis of lymphoma other than BL was suggested. In the remaining
cases (12%), the opinion of the panel included – non-diagnostic material; malignancy, but
not lymphoma; no evidence of lymphoma or another malignancy.
Among the 467 histological samples that were submitted by the participant centres as
diagnostic or highly suggestive of lymphoma, a consensus diagnosis was possible in 393
samples, which included 364 (78%) cases that were confirmed as lymphoma irrespective of
the subtype. It was difficult to assess the accuracy of making diagnoses of specific
lymphoma subtypes, as lymphoma subtyping had not been attempted in many cases partly
due to the fact that basic immunohistochemistry was not available in most centres. A
previous study suggested an accuracy of around 75% for the diagnosis of BL in Uganda
(Ogwang et al, 2011).
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Distribution of different lymphoma subsets in sub-Saharan Africa
Cases reviewed
A total of 467 histological specimens were reviewed. This included 132 cases from Lacor
Hospital, Uganda; 86 cases from Kenyatta National Hospital, Kenya; 79 cases from Aga
Khan University Hospital, Kenya; 92 cases from Muhimbili National Hospital, Tanzania; 44
cases from Obafemi Awolowo University, Nigeria; and 34 cases from University College,
Ibadan, Nigeria. Of these cases, 258 (57%) were males, 192 (43%) were females and the
gender was not recorded in 17 cases. Age had not been recorded in10 patients. Among the
rest, 189 (41.4%) patients were children and adolescents (<18 years age). However, Lacor
Hospital was a paediatric hospital and when this institutions’ cases were excluded, there was
85/335 (26%) children and adolescents (<18 years age). Among them, the mean and median
age was 35.9 years and 36 years respectively.

NIH-PA Author Manuscript

Among the 188 children and adolescent cases (<18 years age), 114 (62%) were males, 70
(38%) were females and the gender was not recorded in 4 cases. Among the 267 adult cases,
140 (53.5%) were males, 121 (46.5%) were females and the gender was not recorded in 6
cases.
Diagnosis
Among the 467 cases, the panel found 393 cases to be assessable. This included 312 cases of
non-Hodgkin lymphoma (NHL) and 52 cases of Hodgkin lymphoma (HL). 11 cases were
classified as benign lymph node lesions and 18 cases were confirmed as malignancies other
than lymphomas. Among the 188 children and adolescent cases (<18 years age), 160 were
assessable, of which 132 were diagnosed as NHL and 19 as HL. Among the 267 adult cases,
172 of 223 assessable cases were considered NHL and 32were diagnosed as HL.
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In children and adolescents (<18 years age), BL accounted for 82% of all NHLs. However,
other lymphomas such as diffuse large B-cell lymphoma (DLBCL) (7.5%), precursor
lymphoid neoplasms and anaplastic large cell lymphoma, ALK positive were also recorded.
Among the 19 HL encountered in children and adolescents (<18 years age), all but one case
were classical HL (cHL) (Tables 1 & 2).
In adults, DLBCL was the most common NHL, accounting for 55% of all NHLs. However,
a wide variety of other lymphomas, such as chronic lymphocytic leukaemia / small
lymphocytic lymphoma (9%), BL (9%), plasmablastic lymphoma (4%), follicular
lymphoma (FL) (3%) and plasmacytoma (3%) were also noted. Among the 5 cases of FL, 4
were of grade 1-2 and one case had features of grade 3b. Among DLBCL, 2 represented
Richter transformation and, one was a cutaneous DLBCL. A component of FL was
recognized in 9 DLBCLs. The nodular sclerosis subtype of cHL accounted for more than
one-half of NHL cases (Tables 3 & 4).
Clinicopathological correlations
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BL was predominantly a disease in children and adolescents. Even after exclusion of cases
from the paediatric hospital, among the remaining 42 BL cases, more than 75% occurred in
the first two decades of life. The median age for BL was 9 years. Among the 122 cases of
BL where surgical biopsies were evaluated, the male:female ratio was 1:1. The more
common sites of initial presentation of BL among children were abdomen (24%), jaw
(24%), ovary (10%), neck lymph nodes (8%), spleen, liver, pelvis and kidney (~5% each).
The more common sites of initial presentation of BL among adults were ovary (20%),
parotid and jaw (13% each). It is entirely possible that this distribution pattern was as much
due to the method of diagnosis chosen (fine needle versus cutting needle or biopsy) as to the
characteristic distribution pattern of the tumour.
DLBCL was predominantly a disease of adults. After exclusion of cases from the paediatric
hospital, 92% of the remaining 95 cases occurred in adults. The median age for DLBCL was
50 years. The male:female ratio was 1.5:1. The more common sites of initial presentation of
DLBCL in adults were lymph nodes (40%), intestines (8%), stomach (7%), abdomen (7%),
sinonasal/tonsillar/nasopharyngeal (6%), oral cavity (4%) and breast (3%).

NIH-PA Author Manuscript

HL was predominantly a disease of childhood and early adulthood. After exclusion of cases
from the paediatric hospital, nearly 75% of the remaining 50 cases occurred before the age
of 30 years, with a median age of 22 years. Only 10% of cases occurred after the age of 50
years. The male:female ratio was 1.2:1. This pattern is likely to be at least in part due to the
age-structure of the population.
Viral associations
In-situ hybridization for Epstein-Barr virus (EBV) using the EBER-1 probe was attempted
on the paraffin blocks. However, in a large proportion of cases, RNA preservation was
suboptimal for definitive documentation. Among the interpretable cases EBV-association
was documented in 21/27 (78%) of BL, 4/29 (14%) of DLBCL, 6/6 (100%) of plasmablastic
lymphoma and 6/7 (86%) of cHL. Other EBV-positive lymphomas seen at lower frequencies
included 2 cases of peripheral T-cell lymphoma, unspecified; 1 case of follicular lymphoma,
Br J Haematol. Author manuscript; available in PMC 2014 October 23.
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grade 3b; one case of B-cell lymphoma unclassifiable with features intermediate between
DLBCL and BL; one case of B-cell lymphoma unclassifiable with features intermediate
between DLBCL and cHL; and 1 case of NK/T cell lymphoma, nasal type. Documentation
of HIV association among cases on which histology specimens were reviewed was
extremely poor. Among them, a positive documentation of HIV-association was noted in 7
cases of BL, 4 cases of DLBCL, 2 cases of cHL and one case of plasmablastic lymphoma,
and a negative documentation of HIV association was noted in 12 cases of BL.

Improving diagnostic standards in sub-Saharan Africa
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Although in the developed world, the importance of the correct diagnosis is appreciated as a
critical issue, this is still an evolving concept in some of the developing countries, especially
in Africa, as observed by members of our group, who have regularly visited East and West
sub-Saharan African countries for the purposes of reviewing lymphomas for one or more
studies. In particular, there are striking differences in the TAT for lymphoma diagnosis and
in the accuracy of diagnosis - differences that have a profound impact on patient outcome.
The current problems in the practice of lymphoma diagnosis include basing treatment
decisions on FNAC in a large proportion of cases, poor quality histology in a proportion of
cases where biopsies are performed, complete lack of immunohistochemistry and other
supportive investigations, lack of continuing education, and a failure to apply the current
criteria for diagnosis of various lymphoid malignancies. In Africa, a majority of the
laboratories still use the Working Formulation for Clinical Usage, a lymphoma classification
from the early 1980's, which is based on morphology alone and does not include most of the
entities recognized in the last 20 years. Without accurate diagnosis, neither meaningful
research projects nor effective patient management can be instituted. Though there are no
magic answers for an issue of this magnitude, “twinning” or other forms of communication
for teaching purposes between pathologists in institutions in the developed countries and
developing countries seems to be the most likely approach to ensuring sustainable
improvements. Twinning projects focused on lymphomas would help to improve diagnostic
accuracy through capacity building, consultations and both direct and indirect technology
transfer.
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Therefore, a systematic approach aimed at improving the diagnostic standards through
partnerships with institutions in African countries in order to bring them closer to the
standards of practice among their European/North American counterparts would be a helpful
strategy. This approach would allow the education of collaborating African pathologists
with respect to the more recent concepts of lymphoma classification and diagnosis, while
introducing essential tools to modern diagnosis such as immunohistochemistry, molecular
cytogenetics and other molecular tools. Building local capacity to initiate
immunohistochemistry with a limited panel of immunostains would be critical for improving
diagnostic standards.
Tele-pathology, through capturing of still-images and their online submission for discussion
with experts in the field, is yet another strategy that might lead to improvements in
diagnosis. This has been popularized by one of the co-authors (Dr. Nina Hurwitz) whose
inputs into the development of the web-based case discussion site iPath hosted through the
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INCTR (http://www.ipath-network.com/inctr/) have been tremendous. The facility has had
an immense appeal in sub-Saharan Africa, as the provision of a microscope with digital
camera attachment to capture still images is fairly inexpensive. Most of the African centres
we visited have reasonably good internet facilities that enable them to post images online.
The success of this strategy is highly dependent on quality of the histology/cytology
preparations and the onsite pathologist's ability to adequately capture the diagnostic and the
problematic areas on the slide. The dialogue and the discussion following the submission of
images are intended to improve the overall diagnostic standards. Lack of
immunohistochemistry support on lymphomas requiring immunohistochemistry could
restrict the experts in making a specific and definitive diagnosis on these submissions.

Strategies for management of lymphoma patients in sub-Saharan Africa
Burkitt lymphoma
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The clinical syndrome of BL was first recognized in Ugandan children (Burkitt, 1958) and
proved to be an important model tumour because it was the first human tumour to be
associated with a virus (EBV) and with another common infection in equatorial Africa malaria. Another important lesson learnt in the pioneering days of chemotherapy was that
BL is highly sensitive to, and indeed, curable, by chemotherapy alone (Magrath, 2009). This
is fortunate, given that the vast majority of tumours are inoperable at presentation, and
surgery may never be curative, while radiotherapy was then and remains extremely limited
in availability, although, like surgery, is of limited value in the treatment of BL. It is
particularly sad, therefore, that the survival rate of this tumour in equatorial Africa – now
over 90% overall in children in Europe, remains very low and not even measurable – even in
major centres where this would be possible, the quality of the data collected generally
prevents an estimate of the survival rate. A study conducted in Africa in the early 1970's,
although not completed, suggested that a simultaneous rather than sequential combination of
active drugs, consisting of cyclophosphamide, vincristine and methotrexate (COM) would
be more effective at controlling systemic disease (Olweny et al 1980), although at the time,
effective central nervous system (CNS) prophylaxis had not been developed and a number
of isolated CNS relapses were observed. The efficacy of COM in conjunction with effective
CNS prophylaxis has never been tested in the African setting because of resource
limitations, lack of training in the conduct of clinical trials, abandonment of therapy and
poor follow-up. However, a high fraction of major African centres still use a variant of
COM therapy. Thus, in spite of the considerable amount of time that has passed since the
original study, these results provide a reasonable starting point for the present stepwise
approach to the development of BL therapy that is feasible in an African setting where
trained oncologists are few or absent, supportive care is limited and a fraction of patients
(varying with age) will also have AIDS. In contrast, intensive chemotherapy of the kind
used in Europe is not feasible for reasons of cost, complexity of treatment, and the need for
excellent supportive care and management by experienced oncologists, which is currently
not available in Africa.
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Diffuse Large B Cell Lymphoma and AIDS-associated NHLs
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A similar situation pertains with respect to DLBCL, where if any therapy can be called
standard in Africa, it is CHOP (cyclophosphamide, hydroxyrubicin, vincristine and
prednisone). Many patients in Africa do not receive the full complement of drugs, possibly
because hydroxyrubicin is relatively expensive. Limited information is available with
respect to the treatment of DLBCL in Africa. However, recent data has suggested that in
children and young adult patients up to the age of 30-35, the predominant DLBCL subtype
is the germinal centre cell type (Oschlies et al, 2006), which has a better prognosis. Indeed
in one large population-based study, over a third of children diagnosed with DLBCL had a
molecular profile of BL (Klapper et al, 2008). No difference in outcome between
histologically diagnosed DLBCL and BL when treated with BL therapy has been
demonstrated in this young age group in Europe. In a recent study from Uganda, BL
comprised approximately one quarter of all NHL, a high fraction of the remainder were
DLBCL and the majority of patients were less than 20 years of age (Mwakigonja et al. 2008,
Oriol et al, 2008). Thus, for most patients, even with DLBCL, BL therapy may well be a
reasonable and feasible approach for a high fraction of patients; this could have the
advantage of avoiding the use of the more expensive and potentially toxic hyroxyrubicin
without compromising results.

Preliminary results of the INCTR-assisted treatment protocols in subSaharan Africa
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For the reasons provided above, the INCTR BL strategy group opted to conduct a pilot study
using a standardized version of COM as first-line therapy in a simple clinical trial for
previously untreated BL. Guidelines for the safe administration of therapy and the provision
of supportive care were included in the protocol, and cytotoxic drugs and antibiotics were
provided free-of-charge, in addition to salaries and training for local persons to collect
accurate data and follow-up of patients who failed to return for appointments after
completion of therapy. Patients who developed progressive tumour at any time in their
treatment (i.e., during remission induction or after achieving a complete remission) were
treated with a second combination regimen, also felt likely to be feasible in the African
setting, consisting of ifosfamide, mesna and cytosine arabinoside. To date, over 460 patients,
nearly all children, with BL (including the few associated with HIV infection) have been
treated since 2004 in centres in Kenya, Tanzania and Nigeria. High remission rates have
been achieved with front line therapy, and excellent survival rates for the African context
obtained in some centres, although significant variability in survival rates was observed
among different centres – most probably due to failure to complete therapy, or to be treated
with second-line therapy (which was shown to be active) in the presence of progressive
disease in centres with a worse outcome.
Importantly, in addition to markedly improved outcome of treatment compared to patients
treated prior to initiation of the study, follow up and documentation of results have all been
greatly improved. Moreover, the identification of avoidable deaths and the proven efficacy
of the second-line regimen suggest that this result can be improved upon in the coming years
and the benefits extended to additional patients in the same or other African countries.
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Acquiring reliable clinical and pathology data in sub-Saharan Africa
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Laboratory studies require patient tissues and/or fluids, which must be correctly collected,
stored and documented in order that correct results may be obtained and, where appropriate,
correlations made with clinical findings, such that accurate evidence is collected. The
INCTRs strategy for serum and tissue collection is as follows:
Serum samples

NIH-PA Author Manuscript

Ideally, serum samples (from 7-10 ml of blood) should be obtained on at least two
occasions: one immediately prior to treatment (ideally, on the day that treatment begins, but
at least within 72 h prior to the initiation of treatment) and the other immediately before
cycle 2 (within 72 h prior to the initiation of the cycle. Ideally, serum should be stored in
one 2 ml aliquot and the remainder in 1 ml aliquots (3 vials per patient). Each vial should be
labelled with the patient study number (which should be a unique identifier) and date. The
label on the tube should be firmly attached, or if more convenient, an indelible marker pen
or a pen used for writing on glass should be used. Vials should then be placed in a
sequentially numbered serum storage box with standard compartments of a size to hold the
serum vials firmly. All boxes should be kept at −80C. Precautions should be taken against
thawing, and the freezer should be connected to an emergency generator that automatically
switches on in the event of a power failure.
Tissue samples
An attempt to obtain tumour/lymph node samples should be made in every case. Diagnosis
rendered on FNA has limitations, and using only FNA for diagnosis can compromise at the
specific diagnosis and impact on correct treatment. Errors in FNA diagnosis can be difficult
to resolve even during a review undertaken later by a specialist haematopathologist. If an
open or a surgical biopsy is not possible, a needle core biopsy should be attempted. An
imprint of the needle core biopsy or the open biopsy can be used for immediate diagnosis,
on which treatment can be based and initiated. Diagnosis rendered on imprint cytology
should be followed by a more formal diagnosis on histology possibly supported by
immunohistochemistry. Informed consent should be sought from the patients or their
guardians regarding the performance of the procedure prior to obtaining consent for
participation in the treatment protocol.
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Appropriate handling of tissue samples is critical for correct diagnosis and reliable research.
Once the imprints have been obtained, the remainder of the material should arrive at the
pathology service within 30 min of being surgically removed. The tissue should be sectioned
by a pathologist into 3 mm slices for obtaining ‘touch preparations’ or ‘imprints’. At least
two touch preparations should be obtained - one imprint should be air-dried and stained with
May-Grunwald-Giemsa, and the other fixed with cytofix and stained with Papanicolaou.
Tissue slices should then be fixed in 10% buffered formalin at the optimal fixation time of
24 h at room temperature. If the lymph node is large enough, additional slices should be
prepared for cryopreservation. Labelling of frozen samples should be performed similar to
those described for serum, although larger vials and boxes will be required, and frozen
samples should be stored in a different part of the freezer than serum samples.
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Records on storage of frozen serum and tissue samples and on the paraffin block archives
should be maintained on an electronic data base so that data is readily available and
searchable, as well as analysable.
Data Management
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Robust electronic database recording clinical and pathological information is critical for
translational research. The INCTR has a purpose-built database that has been installed in all
its participating centres. It overcomes problems of intermittent internet connection in Africa
because data is entered off-line, then uploaded and synchronized with the central database in
Brussels as data entry for individual patients is completed. This both increases the security
of data storage (because it is now centralized on a secure server) and enables data to be
examined immediately and any necessary queries generated without delay, as local site data
is synchronized with the data kept on the central server immediately it has been entered at
the site level. It also avoids use of e-mail for data transfer with its associated delays and
hazards. The database records all the essential patient presentation data, clinical findings and
results of pathological and imaging investigations. Data regarding treatment and follow-up
is also appended periodically as per standard practices determined by INCTR's Clinical
Trials Office.

Fostering high-quality translational research
A respectful partnership between investigators in Africa and developed countries can indeed
result in high-quality translational research and the establishment of research infrastructure
in Africa working partnership. Within our group, Professor Leoncini and his associates have
been able to establish this. Studies from this group have led to: 1) Identification of
differences between endemic BL and sporadic BL in terms of the differences in the
immunoglobulin gene mutation-rates and the possible role of antigen selection (Bellan et al,
2005); 2) Identification of the role of RBL2 gene in endemic BL and the target genes of
RBL2/p130 (De Falco et al, 2007); 3) Identification of alternate pathogenetic mechanisms
involving microRNA in MYC translocation-negative BL (Leucci et al, 2008); and 4) several
studies on gene and microRNA expression in BL (Leucci et al, 2010; Onnis et al, 2010;
Piccaluga et al, 2011). It should be noted that microRNA studies and studies requiring
immunohistochemistry, ISH or FISH can be performed on formalin-fixed tissue samples.
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Though the opportunities for high-quality research through collaboration with centres in
Africa is huge, investments into improving diagnostic accuracy and infrastructure, and
optimal patient management while maintaining a good clinical and pathology database, are
of paramount importance.

Conclusion
The discovery of BL in Africa has led us to extraordinary achievements in oncology,
medicine, epidemiology and science. Half a century after this discovery, treating African
patients with BL remains a challenge. The study of African lymphomas is likely to lead us to
new discoveries. However, these ventures require robust partnerships between Africa and
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the rest of the world. Improving the infrastructure for accurate diagnosis and optimal patient
management are key to meaningful translational research and scientific advances.

NIH-PA Author Manuscript

Acknowledgments
The INCTR has received support from the office of HIV and AIDS malignancy, National Cancer Institute, USA.

Reference

NIH-PA Author Manuscript
NIH-PA Author Manuscript

Bellan C, Lazzi S, Hummel M, Palummo N, de Santi M, Amato T, Nyagol J, Sabattini E, Lazure T,
Pileri SA, Raphael M, Stein H, Tosi P, Leoncini L. Immunoglobulin gene analysis reveals 2 distinct
cells of origin for EBV-positive and EBV-negative burkitt lymphomas. Blood. 2005; 106:1031–
1036. [PubMed: 15840698]
Burkitt D. A sarcoma involving the jaws in african children. The British Journal of Surgery. 1958;
46:218–223. [PubMed: 13628987]
De Falco G, Leucci E, Lenze D, Piccaluga PP, Claudio PP, Onnis A, Cerino G, Nyagol J, Mwanda W,
Bellan C, Hummel M, Pileri S, Tosi P, Stein H, Giordano A, Leoncini L. Gene-expression analysis
identifies novel RBL2/p130 target genes in endemic burkitt lymphoma cell lines and primary
tumors. Blood. 2007; 110:1301–1307. [PubMed: 17485552]
Kaaya EE, Castanos-Velez E, Ekman M, Mwakigonja A, Carneiro P, Lema L, Kitinya J, Linde A,
Biberfeld P. AIDS and non AIDS-related malignant lymphoma in tanzania. African Health
Sciences. 2006; 6:69–75. [PubMed: 16916294]
Klapper W, Szczepanowski M, Burkhardt B, Berger H, Rosolowski M, Bentink S, Schwaenen C,
Wessendorf S, Spang R, Moller P, Hansmann ML, Bernd HW, Ott G, Hummel M, Stein H, Loeffler
M, Trumper L, Zimmermann M, Reiter A, Siebert R, Molecular Mechanisms in Malignant
Lymphomas Network Project of the Deutsche Krebshilfe. Molecular profiling of pediatric mature
B-cell lymphoma treated in population-based prospective clinical trials. Blood. 2008; 112:1374–
1381. [PubMed: 18509088]
Leucci E, Cocco M, Onnis A, De Falco G, van Cleef P, Bellan C, van Rijk A, Nyagol J, Byakika B,
Lazzi S, Tosi P, van Krieken H, Leoncini L. MYC translocation-negative classical burkitt
lymphoma cases: An alternative pathogenetic mechanism involving miRNA deregulation. The
Journal of Pathology. 2008; 216:440–450. [PubMed: 18802929]
Leucci E, Onnis A, Cocco M, De Falco G, Imperatore F, Giuseppina A, Costanzo V, Cerino G,
Mannucci S, Cantisani R, Nyagol J, Mwanda W, Iriso R, Owang M, Schurfeld K, Bellan C, Lazzi S,
Leoncini L. B-cell differentiation in EBV-positive burkitt lymphoma is impaired at
posttranscriptional level by miRNA-altered expression. International Journal of Cancer.Journal
International Du Cancer. 2010; 126:1316–1326. [PubMed: 19530237]
Magrath I. Lessons from clinical trials in african burkitt lymphoma. Current Opinion in Oncology.
2009; 21:462–468. [PubMed: 19620863]
Mwakigonja AR, Kaaya EE, Mgaya EM. Malignant lymphomas (ML) and HIV infection in tanzania.
Journal of Experimental & Clinical Cancer Research : CR. 2008; 27:9. [PubMed: 18577266]
Ogwang MD, Zhao W, Ayers LW, Mbulaiteye SM. Accuracy of burkitt lymphoma diagnosis in
constrained pathology settings: Importance to epidemiology. Archives of Pathology & Laboratory
Medicine. 2011; 135:445–450. [PubMed: 21466360]
Olweny CL, Katongole-Mbidde E, Otim D, Lwanga SK, Magrath IT, Ziegler JL. Long-term
experience with Burkitt's lymphoma in Uganda. Int J Cancer. 1980; 26:261–266. [PubMed:
7287207]
Onnis A, De Falco G, Antonicelli G, Onorati M, Bellan C, Sherman O, Sayed S, Leoncini L.
Alteration of microRNAs regulated by c-myc in burkitt lymphoma. PloS One. 2010; 5:e12960.
[PubMed: 20930934]
Orem J, Otieno MW, Remick SC. AIDS-associated cancer in developing nations. Current Opinion in
Oncology. 2004; 16:468–476. [PubMed: 15314517]
Oriol A, Ribera JM, Bergua J, Gimenez Mesa E, Grande C, Esteve J, Brunet S, Moreno MJ, Escoda L,
Hernandez-Rivas JM, Hoelzer D. High-dose chemotherapy and immunotherapy in adult burkitt

Br J Haematol. Author manuscript; available in PMC 2014 October 23.

Naresh et al.

Page 13

NIH-PA Author Manuscript

lymphoma: Comparison of results in human immunodeficiency virus-infected and noninfected
patients. Cancer. 2008; 113:117–125. [PubMed: 18457327]
Oschlies I, Klapper W, Zimmermann M, Krams M, Wacker HH, Burkhardt B, Harder L, Siebert R,
Reiter A, Parwaresch R. Diffuse large B-cell lymphoma in pediatric patients belongs
predominantly to the germinal-center type B-cell lymphomas: A clinicopathologic analysis of
cases included in the german BFM (berlin-frankfurt-munster) multicenter trial. Blood. 2006;
107:4047–4052. [PubMed: 16424389]
Otieno MW, Remick SC, Whalen C. Adult burkitt's lymphoma in patients with and without human
immunodeficiency virus infection in kenya. International Journal of Cancer. 2001; 92:687–691.
Piccaluga PP, De Falco G, Kustagi M, Gazzola A, Agostinelli C, Tripodo C, Leucci E, Onnis A,
Astolfi A, Sapienza MR, Bellan C, Lazzi S, Tumwine L, Mawanda M, Ogwang M, Calbi V,
Formica S, Califano A, Pileri SA, Leoncini L. Gene expression analysis uncovers similarity and
differences among burkitt lymphoma subtypes. Blood. 2011; 117:3596–3608. [PubMed:
21245480]
Swerdlow, SH.; Campo, E.; Harris, NL.; Jaffe, ES.; Pileri, SA.; Stein, H.; Thiele, J.; Vardiman, JW.
WHO classification of tumours of haematopoietic and lymphoid tissues. 4th Edition.. IARC; Lyon,
France: 2008.

NIH-PA Author Manuscript
NIH-PA Author Manuscript
Br J Haematol. Author manuscript; available in PMC 2014 October 23.

Naresh et al.

Page 14

Table 1
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Lymphoma subtype among 132 paediatric and adolescent (<18 years) NHL cases
Precursor lymphoid neoplasms

4 (3%)

B lymphoblastic leukaemia/lymphoma

1 (0.7%)

T lymphoblastic leukaemia/lymphoma

1 (0.7%)

Blastic leukaemia/lymphoma, not otherwise specified

2 (1.5%)

Mature B-cell neoplasms

123 (92.5%)

Diffuse large B-cell lymphoma (DLBCL)

10 (7.5%)

Burkitt lymphoma (BL)

109 (82%)

B-cell lymphoma, unclassifiable with features intermediate between DLBCL & BL

4 (3%)

Mature T-cell & NK cell neoplasms

3 (2.2%)

Peripheral T-cell lymphoma, not otherwise specified

1 (0.7%)

Anaplastic large cell lymphoma, ALK positive

2 (1.5%)

NHL, not further classifiable due to technical reasons

2

DLBCL, diffuse large B-cell lymphoma ; BL, Burkitt lymphoma
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Table 2
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Histological subtypes among 19 paediatric and adolescent (<18 years) HL cases
Nodular lymphocyte predominant Hodgkin lymphoma

1 (5%)

Nodular sclerosis classical Hodgkin lymphoma

7 (37%)

Mixed cellularity classical Hodgkin lymphoma

7 (37%)

Lymphocyte-depleted classical Hodgkin lymphoma

4 (21%)
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Table 3
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Lymphoma subtype among 172 adult NHL cases
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Precursor lymphoid neoplasms

8 (4.7%)

B lymphoblastic leukaemia/lymphoma

1 (0.6%)

T lymphoblastic leukaemia/lymphoma

4 (2.4%)

Blastic leukaemia/lymphoma, not otherwise specified

3 (1.8%)

Mature B-cell neoplasms

157 (91.3%)

Chronic lymphocytic leukaemia / small lymphocytic lymphoma

16 (9.4%)

Lymphoplasmacytic lymphoma

1 (0.6%)

Plasmacytoma

5 (3%)

Extranodal marginal zone lymphoma of MALT type

2 (1.2%)

Nodal marginal zone lymphoma

4 (2.4%)

Mantle cell lymphoma

1 (0.6%)

Follicular lymphoma

5 (3%)

Primary cutaneous follicular lymphoma

1 (0.6%)

Diffuse large B-cell lymphoma (DLBCL)

95 (55%)

Plasmablastic lymphoma

6 (3.6%)

Burkitt lymphoma (BL)

15 (9%)

B-cell lymphoma, unclassifiable with features intermediate between DLBCL & BL

5 (3%)

B-cell lymphoma, unclassifiable with features intermediate between DLBCL & classical Hodgkin lymphoma

1 (0.6%)

Mature T-cell & NK cell neoplasms

5 (3%)

Extranodal NK/T cell lymphoma, nasal type

1 (0.6%)

Peripheral T-cell lymphoma, not otherwise specified

3 (1.8%)

Primary cutaneous anaplastic large cell lymphoma

1 (0.6%)

NHL, not further classifiable due to technical reasons

2

DLBCL, diffuse large B-cell lymphoma ; BL, Burkitt lymphoma ; MALT, mucosa-associated lymphoid tissue
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Table 4
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Histological subtypes among 32 cases of HL in adults
Nodular lymphocyte predominant Hodgkin lymphoma

3 (9.4%)

Nodular sclerosis classical Hodgkin lymphoma

17 (53%)

Lymphocyte rich classical Hodgkin lymphoma

1 (3%)

Mixed cellularity classical Hodgkin lymphoma

10 (31.2%)

Lymphocyte depleted classical Hodgkin lymphoma

1 (3%)
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